Skip to main content
SpringerLink
Log in

Breast Cancer

  • Living reference work entry
  • First Online:
Side Effects of Cancer Therapy

  • 34 Accesses

Abstract

The appropriate selection of medical therapeutic interventions in breast cancer patients is a daily challenge for medical oncologists and takes into account disease characteristics such as stage at diagnosis, age and menopausal status, aggressiveness of the disease, and presence or absence of key therapeutic targets such as hormonal receptors and HER2. Knowledge of treatment-related toxicities as well as patient’s comorbidities, preferences, age, etc. is a critical component of an optimal estimation of the benefit versus harm ratio of a specific therapy.

This chapter reviews the side effects of the main medical treatment modalities for breast cancer: chemotherapy, endocrine therapy, target therapy, immunotherapy, and bone-modifying therapeutics in terms of frequency, monitoring, and practical management.

Chapter submitted in August 2022. The date of publication is December 2023.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Zhou J, Giannakakou P. Targeting microtubules for cancer chemotherapy. Curr Med Chem Anticancer Agents. 2005;5(1):65–71.

    Article  CAS  PubMed  Google Scholar 

  2. Martín M, Ruiz Simón A, Ruiz Borrego M, Ribelles N, Rodríguez-Lescure Á, Muñoz-Mateu M, et al. Epirubicin plus cyclophosphamide followed by docetaxel versus Epirubicin plus docetaxel followed by Capecitabine as adjuvant therapy for node-positive early breast cancer: results from the GEICAM/2003-10 study. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33(32):3788–95.

    Article  Google Scholar 

  3. Tannock I, Hill R, Bristow R, Harrington L. The basic science of oncology. 4th ed. New York: McGraw-Hil; 2005.

    Google Scholar 

  4. Kaye SB. New antimetabolites in cancer chemotherapy and their clinical impact. Br J Cancer. 1998;78(Suppl 3):1–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Takimoto C, Calvo E. Principles of oncologic pharmacotherapy. In: Pazdur R, Wagman LD, Camphausen KA, Hoskins WJ, editors. Cancer management: a multidisciplinary approach, vol. 11. London: CMP; 2008.

    Google Scholar 

  6. Norton L. A Gompertzian model of human breast cancer growth. Cancer Res. 1988;48(24 Pt 1):7067–71.

    CAS  PubMed  Google Scholar 

  7. Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, et al. Recommendations for the use of WBC growth factors: American society of clinical oncology clinical practice guideline update. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33(28):3199–212.

    Article  CAS  Google Scholar 

  8. Bonilla L, Ben-Aharon I, Vidal L, Gafter-Gvili A, Leibovici L, Stemmer SM. Dose-dense chemotherapy in nonmetastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials. J Natl Cancer Inst. 2010;102(24):1845–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Petrelli F, Cabiddu M, Coinu A, Borgonovo K, Ghilardi M, Lonati V, et al. Adjuvant dose-dense chemotherapy in breast cancer: a systematic review and meta-analysis of randomized trials. Breast Cancer Res Treat. 2015 Jun;151(2):251–9.

    Article  CAS  PubMed  Google Scholar 

  10. Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med. 2008;358(16):1663–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Swain SM, Jeong J-H, Geyer CEJ, Costantino JP, Pajon ER, Fehrenbacher L, et al. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med. 2010;362(22):2053–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47(1):8–32.

    Article  CAS  PubMed  Google Scholar 

  13. Del Mastro L, De Placido S, Bruzzi P, De Laurentiis M, Boni C, Cavazzini G, et al. Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial. Lancet (London, England). 2015;385(9980):1863–72.

    Article  PubMed  Google Scholar 

  14. Hesketh PJ, Kris MG, Grunberg SM, Beck T, Hainsworth JD, Harker G, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol Off J Am Soc Clin Oncol. 1997;15(1):103–9.

    Article  CAS  Google Scholar 

  15. Grunberg SM, Warr D, Gralla RJ, Rapoport BL, Hesketh PJ, Jordan K, et al. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity – state of the art. Support Care Cancer. 2011;19(Suppl 1):S43–7.

    Article  PubMed  Google Scholar 

  16. Schneider BP, Zhao F, Wang M, Stearns V, Martino S, Jones V, et al. Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30(25):3051–7.

    Article  CAS  Google Scholar 

  17. Quasthoff S, Hartung HP. Chemotherapy-induced peripheral neuropathy. J Neurol. 2002;249(1):9–17.

    Article  CAS  PubMed  Google Scholar 

  18. Hershman DL, Lacchetti C, Loprinzi CL. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American society of clinical oncology clinical practice guideline summary. J Oncol Pract. 2014;10(6):e421–4.

    Article  PubMed  Google Scholar 

  19. Schneider BP, Li L, Radovich M, Shen F, Miller KD, Flockhart DA, et al. Genome-wide association studies for Taxane-induced peripheral neuropathy in ECOG-5103 and ECOG-1199. Clin Cancer Res. 2015;21(22):5082–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Barrett-Lee PJ, Dixon JM, Farrell C, Jones A, Leonard R, Murray N, et al. Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk. Ann Oncol Off J Eur Soc Med Oncol. 2009;20(5):816–27.

    Article  CAS  Google Scholar 

  21. Turner N, Biganzoli L, Di Leo A. Continued value of adjuvant anthracyclines as treatment for early breast cancer. Lancet Oncol. 2015;16(7):e362–9.

    Article  PubMed  Google Scholar 

  22. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97(11):2869–79.

    Article  CAS  PubMed  Google Scholar 

  23. Curigliano G, Cardinale D, Suter T, Plataniotis G, de Azambuja E, Sandri MT, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelines. Ann Oncol Off J Eur Soc Med Oncol. 2012;23(Suppl 7).:vii155–66

    Google Scholar 

  24. Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol Off J Am Soc Clin Oncol. 2002 Mar;20(5):1215–21.

    Article  CAS  Google Scholar 

  25. Sawyer DB. Anthracyclines and heart failure. N Engl J Med. 2013 Mar;368(12):1154–6.

    Article  CAS  PubMed  Google Scholar 

  26. Swain SM, Whaley FS, Gerber MC, Weisberg S, York M, Spicer D, et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 1997;15(4):1318–32.

    Article  CAS  Google Scholar 

  27. Hensley ML, Hagerty KL, Kewalramani T, Green DM, Meropol NJ, Wasserman TH, et al. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(1):127–45.

    Article  CAS  Google Scholar 

  28. Von Hoff DD, Layard MW, Basa P, Davis HLJ, Von Hoff AL, Rozencweig M, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91(5):710–7.

    Article  Google Scholar 

  29. Legha SS, Benjamin RS, Mackay B, Ewer M, Wallace S, Valdivieso M, et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med. 1982 Feb;96(2):133–9.

    Article  CAS  PubMed  Google Scholar 

  30. Batist G, Ramakrishnan G, Rao CS, Chandrasekharan A, Gutheil J, Guthrie T, et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2001;19(5):1444–54.

    Article  CAS  Google Scholar 

  31. O’Brien MER, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol Off J Eur Soc Med Oncol. 2004 Mar;15(3):440–9.

    Article  Google Scholar 

  32. Yamaguchi N, Fujii T, Aoi S, Kozuch PS, Hortobagyi GN, Blum RH. Comparison of cardiac events associated with liposomal doxorubicin, epirubicin and doxorubicin in breast cancer: a Bayesian network meta-analysis. Eur J Cancer. 2015;51(16):2314–20.

    Article  CAS  PubMed  Google Scholar 

  33. Benson AB 3rd, Ajani JA, Catalano RB, Engelking C, Kornblau SM, Martenson JAJ, et al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol Off J Am Soc Clin Oncol. 2004;22(14):2918–26.

    Article  CAS  Google Scholar 

  34. Kornblau S, Benson AB, Catalano R, Champlin RE, Engelking C, Field M, et al. Management of cancer treatment-related diarrhea. Issues and therapeutic strategies. J Pain Symptom Manag. 2000;19(2):118–29.

    Article  CAS  Google Scholar 

  35. Palmer KR, Corbett CL, Holdsworth CD. Double-blind cross-over study comparing loperamide, codeine and diphenoxylate in the treatment of chronic diarrhea. Gastroenterology. 1980;79(6):1272–5.

    Article  CAS  PubMed  Google Scholar 

  36. Goumas P, Naxakis S, Christopoulou A, Chrysanthopoulos C, Nikolopoulou VV, Kalofonos HP. Octreotide acetate in the treatment of fluorouracil-induced diarrhea. Oncologist. 1998;3(1):50–3.

    Article  CAS  PubMed  Google Scholar 

  37. Peterson DE, Boers-Doets CB, Bensadoun RJ, Herrstedt J. Management of oral and gastrointestinal mucosal injury: ESMO clinical practice guidelines for diagnosis, treatment, and follow-up. Ann Oncol Off J Eur Soc Med Oncol. 2015;26(Suppl 5):v139–51.

    Article  Google Scholar 

  38. McGuire DB, Fulton JS, Park J, Brown CG, Correa MEP, Eilers J, et al. Systematic review of basic oral care for the management of oral mucositis in cancer patients. Support care cancer Off J Multinatl Assoc Support Care Cancer. 2013;21(11):3165–77.

    Google Scholar 

  39. Rubenstein EB, Peterson DE, Schubert M, Keefe D, McGuire D, Epstein J, et al. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer. 2004;100(9 Suppl):2026–46.

    Article  PubMed  Google Scholar 

  40. Anderson PM, Schroeder G, Skubitz KM. Oral glutamine reduces the duration and severity of stomatitis after cytotoxic cancer chemotherapy. Cancer. 1998;83(7):1433–9.

    Article  CAS  PubMed  Google Scholar 

  41. Peterson DE, Jones JB, Petit RG 2nd. Randomized, placebo-controlled trial of Saforis for prevention and treatment of oral mucositis in breast cancer patients receiving anthracycline-based chemotherapy. Cancer. 2007;109(2):322–31.

    Article  CAS  PubMed  Google Scholar 

  42. Wymenga AN, van der Graaf WT, Hofstra LS, Spijkervet FK, Timens W, Timmer-Bosscha H, et al. Phase I study of transforming growth factor-beta3 mouthwashes for prevention of chemotherapy-induced mucositis. Clin Cancer Res. 1999;5(6):1363–8.

    CAS  PubMed  Google Scholar 

  43. Gorzegno G, Cerutti S, Sperone P. Effect of granulocyte macrophage colony stimulating factor (GM-CSF) mouthwash on grade III chemotherapy-induced oral mucositits. Proc Am Soc Clin Oncol. 1999;18:554 (abstract).

    Google Scholar 

  44. Hejna M, Köstler WJ, Raderer M, Steger GG, Brodowicz T, Scheithauer W, et al. Decrease of duration and symptoms in chemotherapy-induced oral mucositis by topical GM-CSF: results of a prospective randomised trial. Eur J Cancer. 2001;37(16):1994–2002.

    Article  CAS  PubMed  Google Scholar 

  45. Bjordal JM, Bensadoun R-J, Tunèr J, Frigo L, Gjerde K, Lopes-Martins RA. A systematic review with meta-analysis of the effect of low-level laser therapy (LLLT) in cancer therapy-induced oral mucositis. Support Care Cancer. 2011 Aug;19(8):1069–77.

    Article  PubMed  Google Scholar 

  46. Hermelink K. Chemotherapy and cognitive function in breast cancer patients: the so-called chemo brain. J Natl Cancer Inst Monogr. 2015;2015(51):67–9.

    Article  PubMed  Google Scholar 

  47. Falleti MG, Sanfilippo A, Maruff P, Weih L, Phillips K-A. The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: a meta-analysis of the current literature. Brain Cogn. 2005;59(1):60–70.

    Article  PubMed  Google Scholar 

  48. Poppelreuter M, Weis J, Külz AK, Tucha O, Lange KW, Bartsch HH. Cognitive dysfunction and subjective complaints of cancer patients. A cross-sectional study in a cancer rehabilitation Centre. Eur J Cancer. 2004;40(1):43–9.

    Article  CAS  PubMed  Google Scholar 

  49. Bender CM, Pacella ML, Sereika SM, Brufsky AM, Vogel VG, Rastogi P, et al. What do perceived cognitive problems reflect? J Support Oncol. 2008;6(5):238–42.

    PubMed  PubMed Central  Google Scholar 

  50. Meyers CA. How chemotherapy damages the central nervous system. J Biol. 2008;7(4):11.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Ahles TA, Saykin AJ, Furstenberg CT, Cole B, Mott LA, Skalla K, et al. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol Off J Am Soc Clin Oncol. 2002;20(2):485–93.

    Article  CAS  Google Scholar 

  52. Wefel JS, Saleeba AK, Buzdar AU, Meyers CA. Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer. 2010;116(14):3348–56.

    Article  PubMed  Google Scholar 

  53. Ahles TA, Root JC, Ryan EL. Cancer- and cancer treatment-associated cognitive change: an update on the state of the science. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30(30):3675–86.

    Article  CAS  Google Scholar 

  54. Han R, Yang YM, Dietrich J, Luebke A, Mayer-Pröschel M, Noble M. Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system. J Biol. 2008;7(4):12.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Kreukels BPC, Hamburger HL, de Ruiter MB, van Dam FSAM, Ridderinkhof KR, Boogerd W, et al. ERP amplitude and latency in breast cancer survivors treated with adjuvant chemotherapy. Clin Neurophysiol Off J Int Fed Clin Neurophysiol. 2008;119(3):533–41.

    Article  Google Scholar 

  56. Jim HSL, Phillips KM, Chait S, Faul LA, Popa MA, Lee Y-H, et al. Meta-analysis of cognitive functioning in breast cancer survivors previously treated with standard-dose chemotherapy. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30(29):3578–87.

    Article  CAS  Google Scholar 

  57. Runowicz CD, Leach CR, Henry NL, Henry KS, Mackey HT, Cowens-Alvarado RL, et al. American Cancer Society/American Society of Clinical Oncology breast cancer survivorship care guideline. J Clin Oncol Off J Am Soc Clin Oncol. 2016;34(6):611–35.

    Article  CAS  Google Scholar 

  58. Schover LR, Yetman RJ, Tuason LJ, Meisler E, Esselstyn CB, Hermann RE, et al. Partial mastectomy and breast reconstruction. A comparison of their effects on psychosocial adjustment, body image, and sexuality. Cancer. 1995;75(1):54–64.

    Article  CAS  PubMed  Google Scholar 

  59. Wilmoth MC, Ross JA. Women’s perception. Breast cancer treatment and sexuality. Cancer Pract. 1997;5(6):353–9.

    CAS  PubMed  Google Scholar 

  60. Bakewell RT, Volker DL. Sexual dysfunction related to the treatment of young women with breast cancer. Clin J Oncol Nurs. 2005 Dec;9(6):697–702.

    Article  PubMed  Google Scholar 

  61. Avis NE, Crawford S, Manuel J. Psychosocial problems among younger women with breast cancer. Psychooncology. 2004;13(5):295–308.

    Article  PubMed  Google Scholar 

  62. Bartula I, Sherman KA. Screening for sexual dysfunction in women diagnosed with breast cancer: systematic review and recommendations. Breast Cancer Res Treat. 2013;141(2):173–85.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Goldfarb SB, Dickler M, Sit L, Fruscione M, Barz T, Atkinson T, et al. Sexual dysfunction in women with breast cancer: prevalence and severity. J Clin Oncol [Internet]. 2009;27(15_suppl):9558. Available from: https://ascopubs.org/doi/abs/10.1200/jco.2009.27.15_suppl.9558

  64. Hummel SB, van Lankveld JJDM, Oldenburg HSA, Hahn DEE, Kieffer JM, Gerritsma MA, et al. Efficacy of internet-based cognitive behavioral therapy in improving sexual functioning of breast cancer survivors: results of a randomized controlled trial. J Clin Oncol [Internet]. 2017;35(12):1328–40. https://doi.org/10.1200/JCO.2016.69.6021.

    Article  PubMed  Google Scholar 

  65. Goetsch MF, Lim JY, Caughey AB. A practical solution for dyspareunia in breast cancer survivors: a randomized controlled trial. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33(30):3394–400.

    Article  CAS  Google Scholar 

  66. Lee SJ, Schover LR, Partridge AH, Patrizio P, Wallace WH, Hagerty K, et al. American society of clinical oncology recommendations on fertility preservation in cancer patients. J Clin Oncol Off J Am Soc Clin Oncol. 2006 Jun;24(18):2917–31.

    Article  Google Scholar 

  67. Howard-Anderson J, Ganz PA, Bower JE, Stanton AL. Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: a systematic review. J Natl Cancer Inst. 2012;104(5):386–405.

    Article  PubMed  Google Scholar 

  68. Ruddy KJ, Gelber SI, Tamimi RM, Ginsburg ES, Schapira L, Come SE, et al. Prospective study of fertility concerns and preservation strategies in young women with breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32(11):1151–6.

    Article  Google Scholar 

  69. Loren AW, Mangu PB, Beck LN, Brennan L, Magdalinski AJ, Partridge AH, et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31(19):2500–10.

    Article  Google Scholar 

  70. Peccatori FA, Azim HAJ, Orecchia R, Hoekstra HJ, Pavlidis N, Kesic V, et al. Cancer, pregnancy and fertility: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol. 2013;24(Suppl 6):vi160–70.

    Google Scholar 

  71. Lambertini M, Del Mastro L, Pescio MC, Andersen CY, Azim HAJ, Peccatori FA, et al. Cancer and fertility preservation: international recommendations from an expert meeting, vol. 14. BMC Medicine; 2016. p. 1.

    Google Scholar 

  72. Paluch-Shimon S, Pagani O, Partridge AH, Bar-Meir E, Fallowfield L, Fenlon D, et al. Second international consensus guidelines for breast cancer in young women (BCY2). Breast. 2016;26:87–99.

    Article  PubMed  Google Scholar 

  73. Lambertini M, Ginsburg ES, Partridge AH. Update on fertility preservation in young women undergoing breast cancer and ovarian cancer therapy. Curr Opin Obstet Gynecol. 2015;27(1):98–107.

    Article  PubMed  Google Scholar 

  74. Praga C, Bergh J, Bliss J, Bonneterre J, Cesana B, Coombes RC, et al. Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23(18):4179–91.

    Article  CAS  Google Scholar 

  75. Smith RE, Bryant J, DeCillis A, Anderson S. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and bowel project experience. J Clin Oncol Off J Am Soc Clin Oncol. 2003;21(7):1195–204.

    Article  CAS  Google Scholar 

  76. Churpek JE, Marquez R, Neistadt B, Claussen K, Lee MK, Churpek MM, et al. Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia. Cancer. 2016;122(2):304–11.

    Article  CAS  PubMed  Google Scholar 

  77. Lyman GH, Dale DC, Wolff DA, Culakova E, Poniewierski MS, Kuderer NM, et al. Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(17):2914–24.

    Article  Google Scholar 

  78. Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet (London, England). 2013;381(9869):805–16.

    Article  CAS  PubMed  Google Scholar 

  79. Gray RG, Rea D, Handley K, Bowden SJ, Perry P, Earl HM, et al. aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J Clin Oncol [Internet]. 2013;31(18_suppl):5. https://doi.org/10.1200/jco.2013.31.18_suppl.5.

    Article  Google Scholar 

  80. Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, et al. Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial. J Natl Cancer Inst. 2014;106(1):djt337.

    Article  PubMed  Google Scholar 

  81. Bonneterre J, Thürlimann B, Robertson JF, Krzakowski M, Mauriac L, Koralewski P, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or Arimidex randomized group efficacy and tolerability study. J Clin Oncol Off J Am Soc Clin Oncol. 2000;18(22):3748–57.

    Article  CAS  Google Scholar 

  82. Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the international Letrozole breast cancer group. J Clin Oncol Off J Am Soc Clin Oncol. 2003;21(11):2101–9.

    Article  CAS  Google Scholar 

  83. Paridaens RJ, Dirix LY, Beex LV, Nooij M, Cameron DA, Cufer T, et al. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European organisation for research and treatment of cancer breast cancer cooperative group. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(30):4883–90.

    Article  CAS  Google Scholar 

  84. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015;386(10001):1341–52.

    Article  Google Scholar 

  85. Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Knauer M, Moik M, et al. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian breast and colorectal cancer study group trial 12. Ann Oncol Off J Eur Soc Med Oncol. 2015;26(2):313–20.

    Article  CAS  Google Scholar 

  86. Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, Láng I, et al. Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med [Internet]. 2018;379(2):122–37. https://doi.org/10.1056/NEJMoa1803164.

    Article  CAS  PubMed  Google Scholar 

  87. Goss PE, Ingle JN, Pritchard KI, Ellis MJ, Sledge GW, Budd GT, et al. Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27 – a randomized controlled phase III trial. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31(11):1398–404.

    Article  CAS  Google Scholar 

  88. Smith I, Yardley D, Burris H, De Boer R, Amadori D, McIntyre K, et al. Comparative efficacy and safety of adjuvant letrozole versus anastrozole in postmenopausal patients with hormone receptor-positive, node-positive early breast cancer: final results of the randomized phase III femara versus anastrozole clinical evaluation. J Clin Oncol Off J Am Soc Clin Oncol. 2017;35(10):1041–8.

    Article  CAS  Google Scholar 

  89. Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a north American trial. J Clin Oncol Off J Am Soc Clin Oncol. 2002;20(16):3386–95.

    Article  CAS  Google Scholar 

  90. Howell A, Robertson JFR, Quaresma Albano J, Aschermannova A, Mauriac L, Kleeberg UR, et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol Off J Am Soc Clin Oncol. 2002;20(16):3396–403.

    Article  CAS  Google Scholar 

  91. Howell A, Robertson JFR, Abram P, Lichinitser MR, Elledge R, Bajetta E, et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol Off J Am Soc Clin Oncol. 2004;22(9):1605–13.

    Article  CAS  Google Scholar 

  92. Johnston SR, Kilburn LS, Ellis P, Dodwell D, Cameron D, Hayward L, et al. Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicent. Lancet Oncol. 2013 Sep;14(10):989–98.

    Article  CAS  PubMed  Google Scholar 

  93. Buzdar A, Howell A, Cuzick J, Wale C, Distler W, Hoctin-Boes G, et al. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol. 2006;7(8):633–43.

    Article  CAS  PubMed  Google Scholar 

  94. Mouridsen H, Giobbie-Hurder A, Goldhirsch A, Thürlimann B, Paridaens R, Smith I, et al. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med. 2009;361(8):766–76.

    Article  CAS  PubMed  Google Scholar 

  95. Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, et al. Survival and safety of exemestane versus tamoxifen after 2-3 years’ tamoxifen treatment (intergroup Exemestane study): a randomised controlled trial. Lancet (London, England). 2007;369(9561):559–70.

    Article  CAS  PubMed  Google Scholar 

  96. ACOG Practice Bulletin No. 126. Management of gynecologic issues in women with breast cancer. Obstet Gynecol. 2012;119(3):666–82.

    Article  Google Scholar 

  97. Gerber B, Krause A, Müller H, Reimer T, Külz T, Makovitzky J, et al. Effects of adjuvant tamoxifen on the endometrium in postmenopausal women with breast cancer: a prospective long-term study using transvaginal ultrasound. J Clin Oncol Off J Am Soc Clin Oncol. 2000;18(20):3464–70.

    Article  CAS  Google Scholar 

  98. Neri F, Maggino T. Surveillance of endometrial pathologies, especially for endometrial cancer, of breast cancer patients under tamoxifen treatment. Eur J Gynaecol Oncol. 2009;30(4):357–60.

    CAS  PubMed  Google Scholar 

  99. Soini T, Hurskainen R, Grénman S, Mäenpää J, Paavonen J, Pukkala E. Cancer risk in women using the levonorgestrel-releasing intrauterine system in Finland. Obstet Gynecol. 2014;124(2 Pt 1):292–9.

    Article  CAS  PubMed  Google Scholar 

  100. van de Velde CJH, Rea D, Seynaeve C, Putter H, Hasenburg A, Vannetzel J-M, et al. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet (London, England). 2011;377(9762):321–31.

    Article  PubMed  Google Scholar 

  101. Garber JE, Halabi S, Tolaney SM, Kaplan E, Archer L, Atkins JN, et al. Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer. J Natl Cancer Inst. 2010;102(13):942–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  102. Boekhout AH, Vincent AD, Dalesio OB, van den Bosch J, Foekema-Töns JH, Adriaansz S, et al. Management of hot flashes in patients who have breast cancer with venlafaxine and clonidine: a randomized, double-blind, placebo-controlled trial. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(29):3862–8.

    Article  CAS  Google Scholar 

  103. Leon-Ferre RA, Novotny PJ, Wolfe EG, Faubion SS, Ruddy KJ, Flora D, et al. Oxybutynin vs placebo for hot flashes in women with or without breast cancer: a randomized, double-blind clinical trial (ACCRU SC-1603). JNCI Cancer Spectr [Internet]. 2019;4(1):pkz088–pkz088. Available from: https://pubmed.ncbi.nlm.nih.gov/32337497

  104. Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, et al. Tamoxifen for the prevention of breast cancer: current status of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst. 2005;97(22):1652–62.

    Article  CAS  PubMed  Google Scholar 

  105. Pavlidis NA, Petris C, Briassoulis E, Klouvas G, Psilas C, Rempapis J, et al. Clear evidence that long-term, low-dose tamoxifen treatment can induce ocular toxicity. A prospective study of 63 patients. Cancer. 1992;69(12):2961–4.

    Article  CAS  PubMed  Google Scholar 

  106. Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Láng I, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014;371(2):107–18.

    Article  PubMed  PubMed Central  Google Scholar 

  107. Arem H, Sorkin M, Cartmel B, Fiellin M, Capozza S, Harrigan M, et al. Exercise adherence in a randomized trial of exercise on aromatase inhibitor arthralgias in breast cancer survivors: the hormones and physical exercise (HOPE) study. J Cancer Surviv [Internet]. 2016/01/19. 2016;10(4):654–62. Available from: https://pubmed.ncbi.nlm.nih.gov/26782031

  108. Chen L, Lin C-C, Huang T-W, Kuan Y-C, Huang Y-H, Chen H-C, et al. Effect of acupuncture on aromatase inhibitor-induced arthralgia in patients with breast cancer: A meta-analysis of randomized controlled trials. The Breast [Internet]. 2017;33:132–8. Available from: http://www.sciencedirect.com/science/article/pii/S0960977617304228

  109. Henry NL, Unger JM, Schott AF, Fehrenbacher L, Flynn PJ, Prow DM, et al. Randomized, multicenter, placebo-controlled clinical trial of duloxetine versus placebo for aromatase inhibitor-associated arthralgias in early-stage breast cancer: SWOG S1202. J Clin Oncol [Internet]. 2018;36(4):326–32. Available from: https://europepmc.org/articles/PMC5805479

  110. Dent SF, Gaspo R, Kissner M, Pritchard KI. Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer. Breast Cancer Res Treat. 2011;126(2):295–310.

    Article  CAS  PubMed  Google Scholar 

  111. Shapiro CL, Van Poznak C, Lacchetti C, Kirshner J, Eastell R, Gagel R, et al. Management of osteoporosis in survivors of adult cancers with nonmetastatic disease: ASCO clinical practice guideline. J Clin Oncol [Internet]. 2019 18;37(31):2916–46. https://doi.org/10.1200/JCO.19.01696

  112. Body J-J. Prevention and treatment of side-effects of systemic treatment: bone loss. Ann Oncol Off J Eur Soc Med Oncol. 2010;21(Suppl 7).:vii180–5

    Google Scholar 

  113. Hadji P, Coleman RE, Wilson C, Powles TJ, Clézardin P, Aapro M, et al. Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European panel. Ann Oncol Off J Eur Soc Med Oncol. 2016;27(3):379–90.

    Article  CAS  Google Scholar 

  114. Ellis GK, Bone HG, Chlebowski R, Paul D, Spadafora S, Fan M, et al. Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study. Breast Cancer Res Treat. 2009;118(1):81–7.

    Article  CAS  PubMed  Google Scholar 

  115. Gnant M, Pfeiler G, Dubsky PC, Hubalek M, Greil R, Jakesz R, et al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet (London, England). 2015;386(9992):433–43.

    Article  CAS  PubMed  Google Scholar 

  116. Amir E, Seruga B, Niraula S, Carlsson L, Ocaña A. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst. 2011;103(17):1299–309.

    Article  CAS  PubMed  Google Scholar 

  117. Phillips K-A, Ribi K, Sun Z, Stephens A, Thompson A, Harvey V, et al. Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial. Breast. 2010;19(5):388–95.

    Article  PubMed  Google Scholar 

  118. Schilder CM, Seynaeve C, Beex LV, Boogerd W, Linn SC, Gundy CM, et al. Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(8):1294–300.

    Article  CAS  Google Scholar 

  119. Phillips K-A, Regan MM, Ribi K, Francis PA, Puglisi F, Bellet M, et al. Adjuvant ovarian function suppression and cognitive function in women with breast cancer. Br J Cancer. 2016;114(9):956–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  120. Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol. 1999;26(4 Suppl 12):60–70.

    CAS  PubMed  Google Scholar 

  121. Wolff AC, Hammond MEH, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31(31):3997–4013.

    Article  Google Scholar 

  122. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–92.

    Article  CAS  PubMed  Google Scholar 

  123. Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23(19):4265–74.

    Article  CAS  Google Scholar 

  124. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353(16):1659–72.

    Article  CAS  PubMed  Google Scholar 

  125. Joensuu H, Kellokumpu-Lehtinen P-L, Bono P, Alanko T, Kataja V, Asola R, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med [Internet]. 2006;354(8):809–20. https://doi.org/10.1056/NEJMoa053028.

  126. Perez EA, Suman VJ, Davidson NE, Gralow JR, Kaufman PA, Visscher DW, et al. Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2011 Dec;29(34):4491–7.

    Article  CAS  Google Scholar 

  127. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365(14):1273–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  128. Friedländer E, Barok M, Szöllosi J, Vereb G. ErbB-directed immunotherapy: antibodies in current practice and promising new agents. Immunol Lett. 2008;116(2):126–40.

    Article  PubMed  Google Scholar 

  129. Baselga J, Cortés J, Kim S-B, Im S-A, Hegg R, Im Y-H, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366(2):109–19.

    Article  CAS  PubMed  Google Scholar 

  130. Swain SM, Baselga J, Kim S-B, Ro J, Semiglazov V, Campone M, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372(8):724–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  131. Gianni L, Pienkowski T, Im Y-H, Roman L, Tseng L-M, Liu M-C, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(1):25–32.

    Article  CAS  PubMed  Google Scholar 

  132. von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med. 2017 Jul;377(2):122–31.

    Article  Google Scholar 

  133. Jones AL, Barlow M, Barrett-Lee PJ, Canney PA, Gilmour IM, Robb SD, et al. Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring. Br J Cancer. 2009;100(5):684–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  134. Russell SD, Blackwell KL, Lawrence J, Pippen JEJ, Roe MT, Wood F, et al. Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and bowel project B-31 and the N. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(21):3416–21.

    Article  CAS  Google Scholar 

  135. de Azambuja E, Ponde N, Procter M, Rastogi P, Cecchini RS, Lambertini M, et al. A pooled analysis of the cardiac events in the trastuzumab adjuvant trials. Breast Cancer Res Treat. 2020;179(1):161–71.

    Article  PubMed  Google Scholar 

  136. Suter TM, Procter M, van Veldhuisen DJ, Muscholl M, Bergh J, Carlomagno C, et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol Off J Am Soc Clin Oncol. 2007;25(25):3859–65.

    Article  CAS  Google Scholar 

  137. Martel S, Maurer C, Lambertini M, Pondé N, De Azambuja E. Breast cancer treatment-induced cardiotoxicity. Expert Opin Drug Saf. 2017;16(9):1021–38.

    Article  CAS  PubMed  Google Scholar 

  138. Swain SM, Schneeweiss A, Gianni L, Gao JJ, Stein A, Waldron-Lynch M, et al. Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab. Ann Oncol Off J Eur Soc Med Oncol. 2017;28(4):761–8.

    Article  CAS  Google Scholar 

  139. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355(26):2733–43.

    Article  CAS  PubMed  Google Scholar 

  140. Johnston S, Pippen JJ, Pivot X, Lichinitser M, Sadeghi S, Dieras V, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(33):5538–46.

    Article  CAS  Google Scholar 

  141. Burstein HJ, Sun Y, Dirix LY, Jiang Z, Paridaens R, Tan AR, et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(8):1301–7.

    Article  CAS  Google Scholar 

  142. Chan A, Delaloge S, Holmes FA, Moy B, Iwata H, Harvey VJ, et al. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2016;17(3):367–77.

    Article  CAS  PubMed  Google Scholar 

  143. Saura C, Oliveira M, Feng Y-H, Dai M-S, Hurvitz SA, Kim S-B, et al. Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial. J Clin Oncol [Internet]. 2019;37(15_suppl):1002. https://doi.org/10.1200/JCO.2019.37.15_suppl.1002.

  144. Saura C, Oliveira M, Feng Y-H, Dai M-S, Chen S-W, Hurvitz SA, et al. Neratinib plus capecitabine versus lapatinib plus capecitabine in her2-positive metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: phase III NALA trial. J Clin Oncol Off J Am Soc Clin Oncol. 2020(Jul);JCO2000147.

    Google Scholar 

  145. Murthy RK, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz SA, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2020;382(7):597–609.

    Article  CAS  PubMed  Google Scholar 

  146. Busam KJ, Capodieci P, Motzer R, Kiehn T, Phelan D, Halpern AC. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol. 2001;144(6):1169–76.

    Article  CAS  PubMed  Google Scholar 

  147. Moy B, Goss PE. Lapatinib-associated toxicity and practical management recommendations. Oncologist. 2007;12(7):756–65.

    Article  CAS  PubMed  Google Scholar 

  148. Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer. 2006;6(10):803–12.

    Article  CAS  PubMed  Google Scholar 

  149. Peréz-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol Off J Am Soc Clin Oncol. 2005;23(22):5235–46.

    Article  Google Scholar 

  150. Kris MG, Natale RB, Herbst RS, Lynch TJJ, Prager D, Belani CP, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 2003;290(16):2149–58.

    Article  CAS  PubMed  Google Scholar 

  151. Azim HAJ, Agbor-Tarh D, Bradbury I, Dinh P, Baselga J, Di Cosimo S, et al. Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trial. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31(36):4504–11.

    Article  CAS  Google Scholar 

  152. Sonnenblick A, de Azambuja E, Agbor-Tarh D, Bradbury I, Campbell C, Huang Y, et al. Lapatinib-related rash and breast cancer outcome in the ALTTO phase III randomized trial. J Natl Cancer Inst. 2016;108(8):djw037.

    Article  PubMed  PubMed Central  Google Scholar 

  153. Loriot Y, Perlemuter G, Malka D, Penault-Llorca F, Boige V, Deutsch E, et al. Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy. Nat Clin Pract Oncol. 2008;5(5):268–78.

    Article  CAS  PubMed  Google Scholar 

  154. Awada A, Colomer R, Inoue K, Bondarenko I, Badwe RA, Demetriou G, et al. Neratinib plus paclitaxel vs trastuzumab plus paclitaxel in previously untreated metastatic ERBB2-positive breast cancer: the NEfERT-T randomized clinical trial. JAMA Oncol. 2016;2(12):1557–64.

    Article  PubMed  Google Scholar 

  155. Barcenas CH, Hurvitz SA, Di Palma JA, Bose R, Chien AJ, Iannotti N, et al. Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial. Ann Oncol [Internet]. 2020;31(9):1223–30. Available from: https://www.sciencedirect.com/science/article/pii/S0923753420398331

    Article  CAS  PubMed  Google Scholar 

  156. Uribe JM, Keely SJ, Traynor-Kaplan AE, Barrett KE. Phosphatidylinositol 3-kinase mediates the inhibitory effect of epidermal growth factor on calcium-dependent chloride secretion. J Biol Chem. 1996;271(43):26588–95.

    Article  CAS  PubMed  Google Scholar 

  157. Wong K-K, Fracasso PM, Bukowski RM, Lynch TJ, Munster PN, Shapiro GI, et al. A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin Cancer Res. 2009;15(7):2552–8.

    Article  CAS  PubMed  Google Scholar 

  158. Perez EA, Koehler M, Byrne J, Preston AJ, Rappold E, Ewer MS. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc. 2008;83(6):679–86.

    Article  PubMed  Google Scholar 

  159. Azim H, Azim HAJ, Escudier B. Trastuzumab versus lapatinib: the cardiac side of the story. Cancer Treat Rev. 2009;35(7):633–8.

    Article  CAS  PubMed  Google Scholar 

  160. Spraggs CF, Budde LR, Briley LP, Bing N, Cox CJ, King KS, et al. HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2011 Feb;29(6):667–73.

    Article  CAS  Google Scholar 

  161. Moy B, Rappold E, Williams L, Kelly T, Nicolodi L, Maltzman JD, et al. Hepatobiliary abnormalities in patients with metastatic cancer treated with lapatinib. J Clin Oncol [Internet]. 2009;27(15_suppl):1043. Available from: https://ascopubs.org/doi/abs/10.1200/jco.2009.27.15_suppl.1043

  162. Gomez HL, Doval DC, Chavez MA, Ang PC-S, Aziz Z, Nag S, et al. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(18):2999–3005.

    Article  CAS  Google Scholar 

  163. Teng WC, Oh JW, New LS, Wahlin MD, Nelson SD, Ho HK, et al. Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib. Mol Pharmacol. 2010;78(4):693–703.

    Article  CAS  PubMed  Google Scholar 

  164. Pondé N, Aftimos P, Piccart M. Antibody-drug conjugates in breast cancer: a comprehensive review. Curr Treat Opt Oncol. 2019;20(5):37.

    Article  Google Scholar 

  165. Krop IE, Beeram M, Modi S, Jones SF, Holden SN, Yu W, et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(16):2698–704.

    Article  CAS  Google Scholar 

  166. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  167. Krop IE, Kim S-B, González-Martín A, LoRusso PM, Ferrero J-M, Smitt M, et al. Trastuzumab emtansine versus treatment of physician’s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(7):689–99.

    Article  CAS  PubMed  Google Scholar 

  168. von Minckwitz G, Huang C-S, Mano MS, Loibl S, Mamounas EP, Untch M, et al. Trastuzumab Emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380(7):617–28.

    Article  Google Scholar 

  169. Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med [Internet]. 2020 [cited 2020 Apr 24];382(7):610–21. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1914510

  170. Banerji U, van Herpen CML, Saura C, Thistlethwaite F, Lord S, Moreno V, et al. Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. Lancet Oncol. 2019;20(8):1124–35.

    Article  CAS  PubMed  Google Scholar 

  171. Bardia A, Mayer IA, Vahdat LT, Tolaney SM, Isakoff SJ, Diamond JR, et al. Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer. N Engl J Med. 2019;380(8):741–51.

    Article  CAS  PubMed  Google Scholar 

  172. Bardia A. ASCENT: A randomized phase III study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in patients (pts) with previously treated metastatic triple-negative breast cancer (mTNBC) April 22, 2021. N Engl J Med. 2021;384:1529–1541. https://doi.org/10.1056/NEJMoa2028485. https://www.nejm.org/doi/full/10.1056/NEJMoa2028485

  173. Diéras V, Harbeck N, Budd GT, Greenson JK, Guardino AE, Samant M, et al. Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer: an integrated safety analysis. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32(25):2750–7.

    Article  Google Scholar 

  174. Modi S, Park H, Murthy RK, Iwata H, Tamura K, Tsurutani J, et al. Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low–expressing advanced breast cancer: results from a phase Ib study. J Clin Oncol. 2020;JCO.19.02318

    Google Scholar 

  175. Powell C, Camidge D, Gemma A, Kusumoto M, Baba T, Kuwano K, et al. Abstract P6–17-06: Characterization, monitoring and management of interstitial lung disease in patients with metastatic breast cancer: Analysis of data available from multiple studies of DS-8201a, a HER2-targeted antibody drug conjugate with a topoisomerase I inhibitor payload. In: Cancer Research. American Association for Cancer Research (AACR); 2019. p. P6-17-06-P6-17–06.

    Google Scholar 

  176. Powell C. Risk factors for interstitial lung disease in patients treated with trastuzumab deruxtecan from two interventional studies. Ann Oncol 31:S348–S395. https://doi.org/10.1016/annonc/annonc268.

  177. Pondé N, Ameye L, Lambertini M, Paesmans M, Piccart M, de Azambuja E. Trastuzumab emtansine (T-DM1)-associated cardiotoxicity: pooled analysis in advanced HER2-positive breast cancer. Eur J Cancer. 2020;126:65–73.

    Article  PubMed  Google Scholar 

  178. Chau CH, Steeg PS, Figg WD. Antibody-drug conjugates for cancer. Lancet [Internet]. 2019;394(10200):793–804. https://doi.org/10.1016/S0140-6736(19)31774-X.

    Article  CAS  PubMed  Google Scholar 

  179. Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im S-A, Masuda N, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, pha. Lancet Oncol. 2016;17(4):425–39.

    Article  CAS  PubMed  Google Scholar 

  180. Finn RS, Martin M, Rugo HS, Jones S, Im S-A, Gelmon K, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375(20):1925–36.

    Article  CAS  PubMed  Google Scholar 

  181. Hortobagyi GN, Stemmer SM, Burris HA, Yap Y-S, Sonke GS, Paluch-Shimon S, et al. Ribociclib as first-line therapy for hr-positive, advanced breast cancer. N Engl J Med [Internet]. 2016;375(18):1738–48. https://doi.org/10.1056/NEJMoa1609709.

    Article  CAS  PubMed  Google Scholar 

  182. Goetz MP, Toi M, Campone M, Trédan O, Bourayou N, Sohn J, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol [Internet]. 2017;35(32):3638–46. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85032984371&doi=10.1200%2FJCO.2017.75.6155&partnerID=40&md5=ef04840d1df9253ec98b769bba93119b

    Article  CAS  PubMed  Google Scholar 

  183. Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, et al. MONARCH 2: Abemaciclib in combination with fulvestrant in women with HR+/HER2-advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol [Internet]. 2017;35(25):2875–84. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85027966887&doi=10.1200%2FJCO.2017.73.7585&partnerID=40&md5=499c0a428a05fb134e5c18b360477396

    Article  CAS  PubMed  Google Scholar 

  184. Johnston SRD, Harbeck N, Hegg R, Toi M, Martin M, Shao ZM, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol Off J Am Soc Clin Oncol. 2020(Sep);JCO2002514.

    Google Scholar 

  185. Mayer EL, Gnant MI, DeMichele A, Martin M, Burstein H, Prat A, et al. LBA12 PALLAS: a randomized phase III trial of adjuvant palbociclib with endocrine therapy versus endocrine therapy alone for HR+/HER2-early breast cancer. Ann Oncol [Internet]. 2020;31:S1145. https://doi.org/10.1016/j.annonc.2020.08.2240.

    Article  Google Scholar 

  186. Gnant M, Dueck AC, Frantal S, Martin M, Burstein HJ, Greil R, et al. Adjuvant Palbociclib for early breast cancer: the PALLAS trial results (ABCSG-42/AFT-05/BIG-14-03). J Clin Oncol Off J Am Soc Clin Oncol. 2022;40(3):282–93.

    Article  CAS  Google Scholar 

  187. Mayer EL, Dueck AC, Martin M, Rubovszky G, Burstein HJ, Bellet-Ezquerra M, et al. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. Lancet Oncol [Internet]. 2021;22(2):212–22. https://doi.org/10.1016/S1470-2045(20)30642-2.

    Article  CAS  PubMed  Google Scholar 

  188. Loibl S, Marmé F, Martin M, Untch M, Bonnefoi H, Kim S-B, et al. Palbociclib for residual high-risk invasive HR-positive and HER2-negative early breast cancer – the Penelope-B trial. J Clin Oncol [Internet]. 2021;39(14):1518–30. https://doi.org/10.1200/JCO.20.03639.

    Article  CAS  PubMed  Google Scholar 

  189. Tripathy D, Im S-A, Colleoni M, Franke F, Bardia A, Harbeck N, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol [Internet]. 2018;19(7):904–15. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85047257394&doi=10.1016%2FS1470-2045%2818%2930292-4&partnerID=40&md5=a4fbc5341f63f01914fe98e0f2f4d813

    Article  CAS  PubMed  Google Scholar 

  190. Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im S-A, et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: MONALEESA-3. J Clin Oncol [Internet]. 2018;36(24):2465–72. https://doi.org/10.1200/JCO.2018.78.9909.

    Article  CAS  PubMed  Google Scholar 

  191. Tolaney S, Lam AQ, Mukundan S, Nanda S, Cox J, Barriga S. Abstract P6–15-01: Analysis of renal function in MONARCH 1: A phase 2 study of abemaciclib, a CDK4 & 6 inhibitor, as monotherapy, in patients with HR+/HER2-breast cancer, after chemotherapy for metastatic breast cancer (MBC). Cancer Res [Internet]. 2017;77(4 Supplement):P6–15-01 LP-P6–15–01. Available from: http://cancerres.aacrjournals.org/content/77/4_Supplement/P6-15-01.abstract.

  192. Rugo HS, Huober J, Garcia-Saenz JA, Masuda N, Sohn JH, Andre VAM, et al. Management of abemaciclib-associated adverse events in patients with hormone receptor–positive, human epidermal growth receptor 2–negative advanced breast cancer: safety analysis of MONARCH 2 and MONARCH 3. Oncologist [Internet]. 2020. https://doi.org/10.1002/onco.13531.

  193. Yardley DA, Noguchi S, Pritchard KI, Burris 3rd HA, Baselga J, Gnant M, et al. Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther [Internet]. 2013;30(10):870–84. Available from: https://pubmed.ncbi.nlm.nih.gov/24158787

  194. Piccart M, Hortobagyi GN, Campone M, Pritchard KI, Lebrun F, Ito Y, et al. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†. Ann Oncol Off J Eur Soc Med Oncol. 2014;25(12):2357–62.

    Article  CAS  Google Scholar 

  195. Rugo HS, Seneviratne L, Beck JT, Glaspy JA, Peguero JA, Pluard TJ, et al. Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial. Lancet Oncol. 2017;18(5):654–62.

    Article  CAS  PubMed  Google Scholar 

  196. André F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, et al. Alpelisib for PIK3CA-mutated, hormone receptor–positive advanced breast cancer. N Engl J Med [Internet]. 2019;380(20):1929–40. https://doi.org/10.1056/NEJMoa1813904.

    Article  PubMed  Google Scholar 

  197. André F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, et al. Alpelisib for PIK3CA-mutated, hormone receptor–positive advanced breast cancer. N Engl J Med. 2019;380(20):1929–40.

    Article  PubMed  Google Scholar 

  198. Rugo HS, André F, Yamashita T, Cerda H, Toledano I, Stemmer SM, et al. Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer. Ann Oncol [Internet]. 2020;31(8):1001–10. https://doi.org/10.1016/j.annonc.2020.05.001.

    Article  CAS  PubMed  Google Scholar 

  199. Rugo HS, André F, Yamashita T, Cerda H, Toledano I, Stemmer SM, et al. Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer. Ann Oncol. 2020;31(8):1001–10.

    Article  CAS  PubMed  Google Scholar 

  200. Baretta Z, Mocellin S, Goldin E, Olopade OI, Huo D. Effect of BRCA germline mutations on breast cancer prognosis: A systematic review and meta-analysis. Med (United States) [Internet]. 2016 [cited 2020 Jun 23];95(40). Available from: /pmc/articles/PMC5059054/?report=abstract.

    Google Scholar 

  201. Pothuri B. BRCA1- and BRCA2-related mutations: therapeutic implications in ovarian cancer. Ann Oncol. 2013;24(Suppl 8):viii22–viii27. https://doi.org/10.1093/annonc/mdt307. https://pubmed.ncbi.nlm.nih.gov/24131965/

  202. Nijman SMB. Synthetic lethality: general principles, utility and detection using genetic screens in human cells. FEBS Lett. Elsevier B.V. 2011;585:1–6.

    Google Scholar 

  203. Kelley MR, Logsdon D, Fishel ML. Targeting DNA repair pathways for cancer treatment: What’s new? Future Oncol. Future Medicine Ltd. 2014;10:1215–37. https://pubmed.ncbi.nlm.nih.gov/27749552/

  204. Ledermann JA, Pujade-Lauraine E. Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer. 11, Ther Adv Med Oncol. SAGE Publications Inc.; 2019. 1758835919849753.

    Google Scholar 

  205. Robson M, Im S-A, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med [Internet]. 2017 Aug 10 [cited 2020 Mar 27];377(6):523–33. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28578601.

  206. Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018;379(8):753–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  207. Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med [Internet]. 2021;384(25):2394–405. https://doi.org/10.1056/NEJMoa2105215.

    Article  CAS  PubMed  Google Scholar 

  208. Zimmer AS, Gillard M, Lipkowitz S, Lee JM. Update on PARP inhibitors in breast cancer. Curr Treat Opt Oncol. Springer New York LLC. 2018;19:21.

    Google Scholar 

  209. LaFargue CJ, Dal Molin GZ, Sood AK, Coleman RL. Exploring and comparing adverse events between PARP inhibitors [Internet]. Lancet Oncol. Lancet Publishing Group; 2019 [cited 2020 Jun 23]. 20;e15–28. Available from: /pmc/articles/PMC7292736/?report=abstract.

    Google Scholar 

  210. Zhou JX, Feng LJ, Zhang X. Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: a meta-analysis of randomized controlled trials. Drug Des Devel Ther. 2017;11:3009–17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  211. Hurvitz SA, Gonçalves A, Rugo HS, Lee K, Fehrenbacher L, Mina LA, et al. Talazoparib in patients with a germline BRCA – mutated advanced breast cancer: detailed safety analyses from the phase III EMBRACA trial. Oncologist [Internet]. 2020 [cited 2020 Jul 6];25(3). Available from: https://pubmed.ncbi.nlm.nih.gov/32162822/

  212. Farrés J, Llacuna L, Martin-Caballero J, Martínez C, Lozano JJ, Ampurdanés C, et al. PARP-2 sustains erythropoiesis in mice by limiting replicative stress in erythroid progenitors. Cell Death Differ [Internet]. 2015 Jul 1 [cited 2020 Jul 6];22(7):1144–57. Available from: https://pubmed.ncbi.nlm.nih.gov/25501596/

  213. Wang S, Woodgate S, Potter J, Lawo S, Mikule K. Evaluation of clinical-stage PARP inhibitors in cell-based assays to correlate PARP suppression with functional impact on DNA repair. Eur J Cancer [Internet]. 2016 [cited 2020 Jul 6];69:S123–4. Available from: http://www.ejcancer.com/article/S0959804916329677/fulltext

  214. Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet [Internet]. 2017 [cited 2020 Jul 6];390(10106):1949–61. Available from: https://pubmed.ncbi.nlm.nih.gov/28916367/

  215. Lucarini L, Pini A, Gerace E, Pellicciari R, Masini E, Moroni F. Poly(ADP-ribose) polymerase inhibition with HYDAMTIQ reduces allergen-induced asthma-like reaction, bronchial hyper-reactivity and airway remodelling. J Cell Mol Med [Internet]. 2014 [cited 2020 Jul 6];18(3):468–79. Available from: https://pubmed.ncbi.nlm.nih.gov/24444146/

  216. Grabowski JP, Sehouli J, Glajzer J, Worm M, Zuberbier T, Maurer M, et al. Olaparib desensitization in a patient with recurrent peritoneal cancer. N Engl J Med. United States. 2018;379:2176–7.

    Google Scholar 

  217. Wang Y, Wang L, Zhang F, Zhang C, Deng S, Wang R, et al. Inhibition of PARP prevents angiotensin II-induced aortic fibrosis in rats. Int J Cardiol. 2013;167(5):2285–93.

    Article  PubMed  Google Scholar 

  218. Perrotta I, Brunelli E, Sciangula A, Conforti F, Perrotta E, Tripepi S, et al. iNOS induction and PARP-1 activation in human atherosclerotic lesions: an immunohistochemical and ultrastructural approach. Cardiovasc Pathol Off J Soc Cardiovasc Pathol. 2011;20(4):195–203.

    Article  CAS  Google Scholar 

  219. Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375(22):2154–64.

    Article  CAS  PubMed  Google Scholar 

  220. Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(9):1274–84.

    Article  CAS  PubMed  Google Scholar 

  221. FDA approves atezolizumab for PD-L1 positive unresectable locally advanced or metastatic triple-negative breast cancer | FDA [Internet]. [cited 2020 Jun 22]. Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-atezolizumab-pd-l1-positive-unresectable-locally-advanced-or-metastatic-triple-negative

  222. Heimes AS, Schmidt M. Atezolizumab for the treatment of triple-negative breast cancer. Expert Opin Investig Drugs [Internet]. 2019 Jan 2 [cited 2020 Jun 22];28(1):1–5. Available from: https://pubmed.ncbi.nlm.nih.gov/30474425/

  223. Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med [Internet]. 2018 [cited 2020 Jun 22];379(22):2108–21. Available from: https://pubmed.ncbi.nlm.nih.gov/30345906/

  224. Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im S-A, Yusof MM, et al. KEYNOTE-355: randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer. J Clin Oncol [Internet]. 2020;38(15_suppl):1000. https://doi.org/10.1200/JCO.2020.38.15_suppl.1000.

  225. Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med [Internet]. 2020 [cited 2020 Jun 22];382(9):810–21. Available from: https://pubmed.ncbi.nlm.nih.gov/32101663/

  226. Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kümmel S, et al. Event-free survival with Pembrolizumab in early triple-negative breast cancer. N Engl J Med [Internet]. 2022;386(6):556–67. https://doi.org/10.1056/NEJMoa2112651.

    Article  CAS  PubMed  Google Scholar 

  227. Nanda R, Chow LQM, Dees EC, Berger R, Gupta S, Geva R, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib keynote-012 study. J Clin Oncol [Internet]. 2016 Jul 20 [cited 2020 Jun 22];34(21):2460–7. Available from: https://pubmed.ncbi.nlm.nih.gov/27138582/

  228. Adams S, Schmid P, Rugo HS, Winer EP, Loirat D, Awada A, et al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort a of the phase II KEYNOTE-086 study. Ann Oncol [Internet]. 2019;30(3):397–404. https://doi.org/10.1093/annonc/mdy517.

    Article  CAS  PubMed  Google Scholar 

  229. Adams S, Loi S, Toppmeyer D, Cescon DW, De Laurentiis M, Nanda R, et al. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. Ann Oncol [Internet]. 2019;30(3):405–11. https://doi.org/10.1093/annonc/mdy518.

    Article  CAS  PubMed  Google Scholar 

  230. Dirix LY, Takacs I, Jerusalem G, Nikolinakos P, Arkenau HT, Forero-Torres A, et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN solid tumor study. Breast Cancer Res Treat [Internet]. 2018 [cited 2020 Jun 22];167(3):671–86. Available from: https://pubmed.ncbi.nlm.nih.gov/29063313/

  231. Loibl S, Untch M, Burchardi N, Huober J, Sinn BV, Blohmer J-U, et al. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann Oncol [Internet]. 2019;30(8):1279–88. https://doi.org/10.1093/annonc/mdz158.

    Article  CAS  PubMed  Google Scholar 

  232. Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med [Internet]. 2020 [cited 2020 Mar 26];382(9):810–21. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1910549.

  233. McArthur HL, Ignatiadis M, Guillaume S, Bailey A, Martinez JL, Brandao M, et al. ALEXANDRA/IMpassion030: a phase III study of standard adjuvant chemotherapy with or without atezolizumab in early-stage triple-negative breast cancer. J Clin Oncol. 2019;37(15_suppl).:TPS598–TPS598

    Google Scholar 

  234. Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab – Full Text View – ClinicalTrials.gov [Internet]. [cited 2020 Jul 17]. Available from: https://clinicaltrials.gov/ct2/show/NCT02926196

  235. Eigentler TK, Hassel JC, Berking C, Aberle J, Bachmann O, Grünwald V, et al. Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy [internet]. Cancer Treat Rev [cited 2020 Jun 22]. 2016;45:7–18. W.B. Saunders Ltd. Available from: https://pubmed.ncbi.nlm.nih.gov/26922661/

  236. Corsello SM, Barnabei A, Marchetti P, De Vecchis L, Salvatori R, Torino F. Endocrine side effects induced by immune checkpoint inhibitors [Internet]. J Clin Endocrinol Metab; 2013 [cited 2020 Jun 22]; 98:1361–75. Available from: https://pubmed.ncbi.nlm.nih.gov/23471977/

  237. Brumbaugh AD, Narurkar R, Parikh K, Fanucchi M, Frishman WH. Cardiac Immune-Related Adverse Events in Immune Checkpoint Inhibition Therapy [Internet]. Cardiology in Review. Lippincott Williams and Wilkins; 2019 [cited 2020 Jun 22]; 27:97–107. Available from: https://pubmed.ncbi.nlm.nih.gov/29912044/

  238. D’Abreo N, Adams S. Immune-checkpoint inhibition for metastatic triple-negative breast cancer: safety first? [Internet]. Nat Rev Clin Oncol. Nature Publishing Group; 2019 [cited 2020 Jun 22]; 16:399–400. Available from: https://pubmed.ncbi.nlm.nih.gov/31053774/

  239. Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, et al. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol [Internet]. 2017;28:iv119–42. https://doi.org/10.1093/annonc/mdx225.

    Article  CAS  PubMed  Google Scholar 

  240. Boutros C, Tarhini A, Routier E, Lambotte O, Ladurie FL, Carbonnel F, et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination [Internet]. Nat Rev Clin Oncol. Nature Publishing Group; 2016 [cited 2020 Jun 22]; 13:473–86. Available from: https://pubmed.ncbi.nlm.nih.gov/27141885/.

  241. Emens LA, Cruz C, Eder JP, Braiteh F, Chung C, Tolaney SM, et al. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study. JAMA Oncol [Internet]. 2019 Jan 1 [cited 2020 Jun 22];5(1):74–82. Available from: https://pubmed.ncbi.nlm.nih.gov/30242306/

  242. Santa-Maria CA, Kato T, Park JH, Kiyotani K, Rademaker A, Shah AN, et al. A pilot study of durvalumab and tremelimumab and immunogenomic dynamics in metastatic breast cancer. Oncotarget [Internet]. 2018 [cited 2020 Jun 22];9(27):18985–96. Available from: https://pubmed.ncbi.nlm.nih.gov/29721177/

  243. Adams S, Diamond JR, Hamilton E, Pohlmann PR, Tolaney SM, Chang CW, et al. Atezolizumab plus nab-paclitaxel in the treatment of metastatic triple-negative breast cancer with 2-year survival follow-up: a phase 1b clinical trial. JAMA Oncol [Internet]. 2019 [cited 2020 Jun 22];5(3):334–42. Available from: https://pubmed.ncbi.nlm.nih.gov/30347025/

  244. Dirix LY, Takacs I, Jerusalem G, Nikolinakos P, Arkenau H-T, Forero-Torres A, et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN solid tumor study. Breast Cancer Res Treat. 2018;167(3):671–86.

    Article  CAS  PubMed  Google Scholar 

  245. Naidoo J, Wang X, Woo KM, Iyriboz T, Halpenny D, Cunningham J, et al. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. J Clin Oncol [Internet]. 2017 [cited 2020 Jun 22];35(7):709–17. Available from: https://pubmed.ncbi.nlm.nih.gov/27646942/

  246. Tirumani SH, Ramaiya NH, Keraliya A, Bailey ND, Ott PA, Stephen Hodi F, et al. Radiographic profiling of immune-related adverse events in advanced melanoma patients treated with ipilimumab. Cancer Immunol Res [Internet]. 2015 [cited 2020 Jun 22];3(10):1185–92. Available from: https://pubmed.ncbi.nlm.nih.gov/26100356/

  247. Torino F, Corsello SM, Salvatori R. Endocrinological side-effects of immune checkpoint inhibitors [Internet]. Current Opinion in Oncology. Lippincott Williams and Wilkins; 2016 [cited 2020 Jun 22]; 28:278–87. Available from: https://pubmed.ncbi.nlm.nih.gov/27136136/

  248. Nanda R, Liu MC, Yau C, Asare S, Hylton N, Veer LV, et al. Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): results from I-SPY 2. J Clin Oncol. 2017;35(15_suppl):506.

    Article  Google Scholar 

  249. Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol [Internet]. 2018 Jun 10 [cited 2020 Jul 6];36(17):1714–68. Available from: http://ascopubs.org/doi/10.1200/JCO.2017.77.6385

  250. Piccart MJ, Klijn J, Paridaens R, Nooij M, Mauriac L, Coleman R, Bontenbal M, Awada A, Selleslags J, Van Vreckem A, Van Glabbeke M. Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European organization for research and treatment of cancer investigational drug branch for breast cancer. J Clin Oncol. 1997;15:3149–55.

    Article  CAS  PubMed  Google Scholar 

  251. Esmaeli B, Hidaji L, Adinin RB, Faustina M, Coats C, Arbuckle R, Rivera E, Valero V, Tu SM, Ahmadi MA. Blockage of the lacrimal drainage apparatus as a side effect of docetaxel therapy. Cancer. 2003;98:504–7.

    Article  CAS  PubMed  Google Scholar 

  252. Radishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, Hawkins M, O’Shaughnessy J. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005;23:7794–803.

    Article  Google Scholar 

  253. Rouzaud P, Estivals M, Pujazon MC, Carles P, Lauque D. Respiratory complications of the vinorelbine-mitomycin combination. Rev Mal Respir. 1999;16:81–4.

    CAS  PubMed  Google Scholar 

  254. Goli AK, Osman MN, Koduri M, Byrd RP, Roy TM. A case report of vinorelbine monotherapy-related acute bronchospasm and non-ST elevation acute coronary syndrome. Tenn Med. 104:47–8.

    Google Scholar 

  255. Gregory RK, Smith IE. Vinorelbine – a clinical review. Br J Cancer. 2000;82:1907–13.

    CAS  PubMed  PubMed Central  Google Scholar 

  256. Alberts DS, Muggia FM, Carmichael J, Winer EP, Jahanzeb M, Venook AP, Skubitz KM, Rivera E, Sparano JA, DiBella NJ, Stewart SJ, Kavanagh JJ, Gabizon AA. Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials. Semin Oncol. 2004;31:53–90.

    Article  CAS  PubMed  Google Scholar 

  257. Qin D, Ma J, Xiao J, Tang Z. Effect of brain irradiation on blood-csf barrier permeability of chemotherapeutic agents. Am J Clin Oncol. 1997;20:263–5.

    Article  CAS  PubMed  Google Scholar 

  258. Ebeo CT, Girish MR, Byrd RP, Roy TM, Mehta JB. Methotrexate-induced pulmonary lymphoma. Chest. 2003;123:2150–3.

    Article  PubMed  Google Scholar 

  259. Chang TK, Weber GF, Crespi CL, Waxman DJ. Differential activation of cyclophosphamide and ifosphamide by cytochromes p-450 2b and 3a in human liver microsomes. Cancer Res. 1993;53:5629–37.

    CAS  PubMed  Google Scholar 

  260. Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, et al. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017 Dec;18(12):1688–700.

    Article  CAS  PubMed  Google Scholar 

  261. Diéras V, Miles D, Verma S, Pegram M, Welslau M, Baselga J, et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2017 Jun;18(6):732–42.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut Jules Bordet, Université Libre de Bruxelles (U.L.B.), Hôpital Universitaire de Bruxelles (H.U.B.), Bruxelles, Belgium

    Elisa Agostinetto, Andrea Gombos & Martine Piccart

Authors
  1. Elisa Agostinetto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrea Gombos
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Martine Piccart
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Martine Piccart .

Editor information

Editors and Affiliations

  1. Department of Hematology-Oncology, Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg

    Mario A. Dicato

  2. Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium

    Eric Van Cutsem

Rights and permissions

Reprints and permissions

Copyright information

© 2024 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Agostinetto, E., Gombos, A., Piccart, M. (2024). Breast Cancer. In: Dicato, M.A., Van Cutsem, E. (eds) Side Effects of Cancer Therapy. Springer, Cham. https://doi.org/10.1007/978-3-030-93702-7_2-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-93702-7_2-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-93702-7

  • Online ISBN: 978-3-030-93702-7

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation